MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on brain health disorders, has announced a conference call and webcast scheduled for August 13, 2024, at 8:00 a.m. ET. The event will provide a corporate update and review the company's second quarter 2024 financial results for the period ending June 30, 2024. Interested parties can register for the webcast through a provided link, while analysts wishing to participate in the Q&A session have a separate registration link. A replay of the webcast will be available on MindMed's investor relations website for at least 30 days after the event. Participants are advised to join 15 minutes before the start time.
MindMed (NASDAQ: MNMD), un'azienda biofarmaceutica in fase clinica focalizzata sui disturbi della salute mentale, ha annunciato una conferenza telefonica e una trasmissione in webcast programmata per il 13 agosto 2024, alle 8:00 a.m. ET. L'evento fornirà un aggiornamento aziendale e una revisione dei risultati finanziari del secondo trimestre 2024 per il periodo che termina il 30 giugno 2024. Le parti interessate possono registrarsi per il webcast attraverso un link fornito, mentre gli analisti che desiderano partecipare alla sessione di Q&A hanno un link di registrazione separato. Una registrazione del webcast sarà disponibile sul sito web delle relazioni con gli investitori di MindMed per almeno 30 giorni dopo l'evento. Si consiglia ai partecipanti di unirsi 15 minuti prima dell'orario di inizio.
MindMed (NASDAQ: MNMD), una empresa biofarmacéutica en etapa clínica enfocada en trastornos de salud cerebral, ha anunciado una conferencia telefónica y un webcast programados para el 13 de agosto de 2024, a las 8:00 a.m. ET. El evento ofrecerá una actualización corporativa y revisará los resultados financieros del segundo trimestre de 2024 para el período que finaliza el 30 de junio de 2024. Las partes interesadas pueden registrarse para el webcast a través de un enlace proporcionado, mientras que los analistas que deseen participar en la sesión de preguntas y respuestas tienen un enlace de registro separado. Una grabación del webcast estará disponible en el sitio web de relaciones con inversores de MindMed durante al menos 30 días después del evento. Se recomienda a los participantes unirse 15 minutos antes de la hora de inicio.
MindMed (NASDAQ: MNMD)는 뇌 건강 장애에 집중하는 임상 단계의 생명 공학 회사로서 2024년 8월 13일 오전 8시 (동부 표준시)에 예정된 컨퍼런스 콜 및 웹캐스트를 발표했습니다. 이 행사는 회사 업데이트 및 2024년 2분기 재무 결과 검토를 제공할 것입니다. 관심 있는 당사자는 제공된 링크를 통해 웹캐스트에 등록할 수 있으며, Q&A 세션에 참여하고자 하는 분석가들은 별도의 등록 링크가 있습니다. 행사 후 최소 30일 이상 MindMed의 투자자 관계 웹사이트에서 웹캐스트 재생이 가능합니다. 참가자는 시작 시간 15분 전에 접속할 것을 권장합니다.
MindMed (NASDAQ: MNMD), une entreprise bio-pharmaceutique en phase clinique axée sur les troubles de la santé cérébrale, a annoncé une conférence téléphonique et un webinaire prévus pour le 13 août 2024 à 8h00 ET. Cet événement présentera une mise à jour de l'entreprise et un examen des résultats financiers du deuxième trimestre 2024 pour la période se terminant le 30 juin 2024. Les parties intéressées peuvent s'inscrire pour le webinaire via un lien fourni, tandis que les analystes souhaitant participer à la session de questions-réponses ont un lien d'inscription séparé. Un replay du webinaire sera disponible sur le site Web des relations avec les investisseurs de MindMed pendant au moins 30 jours après l'événement. Les participants sont conseillés de rejoindre 15 minutes avant l'heure de début.
MindMed (NASDAQ: MNMD), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Störungen der Gehirngesundheit konzentriert, hat eine Telefonkonferenz und Webcast für den 13. August 2024 um 8:00 Uhr ET angekündigt. Die Veranstaltung wird ein Update zum Unternehmen und eine Überprüfung der finanziellen Ergebnisse für das zweite Quartal 2024 für den Zeitraum bis zum 30. Juni 2024 bieten. Interessierte Parteien können sich über einen bereitgestellten Link für den Webcast registrieren, während Analysten, die an der Q&A-Session teilnehmen möchten, einen separaten Registrierungslink haben. Eine Wiederholung des Webcasts wird auf der Website der Investor Relations von MindMed für mindestens 30 Tage nach der Veranstaltung verfügbar sein. Es wird den Teilnehmern empfohlen, 15 Minuten vor Beginn anzuwesen.
- None.
- None.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806368517/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: Mind Medicine Inc.
FAQ
When is MindMed (MNMD) hosting its Q2 2024 earnings call?
What will be discussed in MindMed's (MNMD) upcoming conference call?
How can investors access MindMed's (MNMD) Q2 2024 earnings call?
Will there be a replay available for MindMed's (MNMD) Q2 2024 earnings call?
